Conventional anatomical ultrasound used as an adjunct to mammography in women with dense breasts raises breast-cancer detection rates but with low specificity, producing high callback and unnecessary-biopsy rates. A 2013 preclinical study showed that ultrasound molecular imaging (USMI) with clinical-grade microbubbles targeted to the angiogenesis receptor VEGFR2 progressively distinguishes normal mammary tissue, hyperplasia, ductal carcinoma in situ (DCIS), and invasive cancer in a rapid-onset transgenic mouse model, with high accuracy in a mouse screening trial. The authors themselves flagged that every step of this result was unvalidated in humans. The intervening literature resolved part of this: first-in-human trials established human safety, feasibility, and dosing of the clinical-grade VEGFR2-targeted microbubble agent BR55, retrospective human tissue cohorts confirmed that vascular VEGFR2 is upregulated in carcinoma relative to benign lesions (though with only modest discriminatory power), and preclinical work demonstrated volumetric 3D acquisition — but clinical development of the agent stalled, and no human in vivo imaging study has tested the core translation questions: whether the magnitude and timing of VEGFR2 upregulation generalize to human DCIS and early invasive disease, whether the molecular signal separates malignancy from the clinical benign-lesion spectrum at screening prevalence, and whether screening with the method improves detection while reducing callbacks and biopsies. The problem remains open.

Background

In breast-cancer screening, mammographic sensitivity is reduced in women with dense breasts, and adjunct screening with conventional (anatomical) ultrasound increases cancer detection but suffers from low specificity, so it generates many false positives, callbacks, and unnecessary biopsies. Ductal carcinoma in situ (DCIS) is a pre-invasive malignant lesion of the breast ducts; reliably detecting it and early invasive cancer non-invasively is a central goal of breast imaging. Ultrasound molecular imaging (USMI) is a targeted variant of contrast-enhanced ultrasound: the contrast agent is a microbubble — a micron-scale gas-filled vesicle, small enough to remain intravascular — whose shell carries ligands (here an antibody or peptide against vascular endothelial growth factor receptor 2, VEGFR2, also called KDR in humans, a key receptor of tumor neoangiogenesis). After intravenous injection and a delay that lets freely circulating bubbles clear, bubbles adherent to VEGFR2-expressing tumor vessels are destroyed by an acoustic pulse and imaged at low acoustic power in a contrast-specific pulse-inversion mode (which suppresses linear echoes from tissue and retains the nonlinear response of the bubbles), yielding a quantitative molecular imaging signal in arbitrary units (a.u.). The source study (Bachawal et al., Cancer Research, 2013) performed USMI in the FVB/N-Tg(MMTV-PyMT)634Mul transgenic mouse model (a strain in which the mouse mammary tumor virus promoter drives the polyoma middle T oncogene in mammary epithelium), in which mammary tissue progresses from normal through hyperplasia to DCIS and invasive cancer within weeks, using a clinical-grade VEGFR2-targeted microbubble (MB_VEGFR2). The molecular signal rose stepwise with disease stage (normal 1.65 ± 0.17 a.u.; hyperplasia 4.21 ± 1.16; DCIS 15.95 ± 1.31; invasive cancer 78.1 ± 6.31) and correlated strongly with ex vivo VEGFR2 expression (R² = 0.84). At a signal threshold of 4.6 a.u., USMI differentiated benign from malignant mammary entities with 84% sensitivity and 89% specificity, and in a prospective mouse screening trial two blinded readers diagnosed malignant disease correctly in over 95% of cases with a positive predictive value as high as 93%. The authors concluded that the approach could ultimately reduce the high callback rate and number of unnecessary biopsies associated with adjunct ultrasound, while explicitly acknowledging that these results were obtained in a fast-progression mouse model, in a single central two-dimensional imaging plane, with mouse dosing, in a model lacking the benign lesion diversity of clinical practice, and at a disease prevalence far above human screening populations — so that translation to women required substantial further validation.

Problem Statement

The source study demonstrated that VEGFR2-targeted ultrasound molecular imaging (USMI) detects premalignant and early malignant breast disease with high accuracy in a rapid-progression transgenic mouse model. The open problem, stated by the authors themselves as the limitations of that study, is whether this result translates into clinically meaningful early breast cancer detection in women. Its single overarching objective is to establish, in humans, that VEGFR2-targeted USMI reliably identifies DCIS and early invasive breast cancer while rejecting benign breast tissue — good enough to improve screening outcomes. Specifically, resolving the problem requires answering, with linked evidence toward that objective: (1) Generalization of disease-stage signal progression — does the magnitude and temporal pattern of VEGFR2 upregulation observed across normal, hyperplasia, DCIS, and invasive cancer in the mouse model hold for human DCIS and early invasive disease, whose natural history is far slower? (2) Benign-lesion discrimination — can the molecular imaging signal distinguish DCIS and invasive cancer from the benign entities encountered in clinical practice (e.g., fibrocystic change, fibroadenoma, sclerosing adenosis), which the mouse model does not develop? (3) Screening-prevalence performance — do sensitivity, specificity, and positive/negative predictive values measured at the mouse trial's high disease prevalence survive at the low prevalence of human screening populations? (4) Clinical dosing and safety — what are the safe and effective clinical dosing, pharmacokinetics, and clearance of clinical-grade VEGFR2-targeted microbubbles in humans (first-in-human evidence exists, with the clinical-grade VEGFR2/KDR-targeted microbubble BR55 at 0.03-0.08 mL/kg shown safe, but formal clinical pharmacology remains incomplete)? (5) Volumetric acquisition — does imaging the entire breast volume in 3D, rather than a single 2D plane, change the achievable sensitivity, specificity, or the appropriate imaging-signal thresholds? (6) Screening outcome — in prospective trials in women (notably those with mammographically dense breasts), does adjunct VEGFR2-targeted USMI maintain or improve cancer detection rates while reducing unnecessary callbacks and biopsies? These components are scientifically linked: each supplies a condition that the screening-outcome question (component 6) presupposes, so they jointly constitute one translational problem rather than independent deliverables. Because no human in vivo imaging study has yet tested these conditions, resolving the problem consists in determining, from the available human evidence, which components are already satisfied and which remain open, and in stating for each open component the evidence that would settle it.

References

  1. Bachawal SV, Jensen KC, Lutz AM, Gambhir SS, Tranquart F, Tian L, Willmann JK. 'Earlier detection of breast cancer with ultrasound molecular imaging in a transgenic mouse model.' Cancer Research 73(6):1689-1698, 2013. doi:10.1158/0008-5472.CAN-12-3391, https://doi.org/10.1158/0008-5472.CAN-12-3391
  2. Willmann JK, Bonomo L, Testa AC, Rinaldi P, Rindi G, Valluru KS, Petrone G, Martini M, Lutz AM, Gambhir SS. 'Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.' Journal of Clinical Oncology 35(19):2133-2140, 2017. doi:10.1200/JCO.2016.70.8594, https://doi.org/10.1200/JCO.2016.70.8594
  3. Smeenge M, Tranquart F, Mannaerts CK, de Reijke TM, van de Vijver MJ, Laguna MP, Pochon S, de la Rosette JJMCH, Wijkstra H. 'First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study.' Investigative Radiology 52(7):419-427, 2017. doi:10.1097/RLI.0000000000000362, https://doi.org/10.1097/RLI.0000000000000362
  4. Ehling J, Misiewicz M, von Stillfried S, Möckel D, Bzyl J, Pochon S, Lederle W, Knuechel R, Lammers T, Palmowski M, Kiessling F. 'In situ validation of VEGFR-2 and αvβ3 integrin as targets for breast lesion characterization.' Angiogenesis 19(2):245-254, 2016. doi:10.1007/s10456-016-9499-4, https://doi.org/10.1007/s10456-016-9499-4
  5. Wang H, Kaneko OF, Tian L, Hristov D, Willmann JK. 'Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.' Investigative Radiology 50(5):322-329, 2015. doi:10.1097/RLI.0000000000000128, https://doi.org/10.1097/RLI.0000000000000128
  6. Zhou J, Wang H, Zhang H, Lutz AM, Tian L, Hristov D, Willmann JK. 'VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer.' Cancer Research 76(14):4081-4089, 2016. doi:10.1158/0008-5472.CAN-15-3271, https://doi.org/10.1158/0008-5472.CAN-15-3271
  7. Bachawal SV, Jensen KC, Wilson KE, Tian L, Lutz AM, Willmann JK. 'Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging.' Cancer Research 75(12):2501-2509, 2015. doi:10.1158/0008-5472.CAN-14-3361, https://doi.org/10.1158/0008-5472.CAN-14-3361
  8. Bam R, Lown PS, Stern LA, Sharma K, Wilson KE, Bean GR, Lutz AM, Paulmurugan R, Hackel BJ, Dahl J, Abou-Elkacem L. 'Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection.' Clinical Cancer Research 26(9):2140-2150, 2020. doi:10.1158/1078-0432.CCR-19-1655, https://doi.org/10.1158/1078-0432.CCR-19-1655
  9. Bachawal S, Bean GR, Krings G, Wilson KE. 'Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression.' npj Breast Cancer 6:14, 2020. doi:10.1038/s41523-020-0158-y, https://doi.org/10.1038/s41523-020-0158-y
  10. Lau C, Rivas M, Dinalo J, King K, Duddalwar V. 'Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis.' Journal of Ultrasound in Medicine 39(1):19-28, 2020. doi:10.1002/jum.15072, https://doi.org/10.1002/jum.15072
  11. Rix A, Baier J, Kiessling F. 'Molecular Ultrasound Imaging.' Recent Results in Cancer Research 224:557-581, 2026. doi:10.1007/978-3-032-15314-2_17, https://doi.org/10.1007/978-3-032-15314-2_17
  12. Köse G, Darguzyte M, Kiessling F. 'Molecular Ultrasound Imaging.' Nanomaterials 10(10):1935, 2020. doi:10.3390/nano10101935, https://doi.org/10.3390/nano10101935
  13. Abou-Elkacem L, Bachawal SV, Willmann JK. 'Ultrasound molecular imaging: Moving toward clinical translation.' European Journal of Radiology 84(9):1685-1693, 2015. doi:10.1016/j.ejrad.2015.03.016, https://doi.org/10.1016/j.ejrad.2015.03.016
  14. Zhong J, Su M, Jiang Y, Huang L, Chen Y, Huang Z, Zhang X. 'VEGFR2 targeted microbubble-based ultrasound molecular imaging improving the diagnostic sensitivity of microinvasive cervical cancer.' Journal of Nanobiotechnology 21:220, 2023. doi:10.1186/s12951-023-01984-2, https://doi.org/10.1186/s12951-023-01984-2
  15. ClinicalTrials.gov record NCT03493464, 'BR55 in Characterization of Ovarian Lesions' (status: terminated; reason: sponsor decision, expiration of available study agent), https://clinicaltrials.gov/study/NCT03493464
  16. ClinicalTrials.gov record NCT03486327, 'Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions' (status: terminated; reason: sponsor decision, expiration of available study agent), https://clinicaltrials.gov/study/NCT03486327